We provide you with 20 years of free, institutional-grade data for HGEN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of HGEN. Explore the full financial landscape of HGEN stock.
| Reported Date | CIK | Ticker | Type |
|---|
Humanigen Inc(NASDAQ:HGEN) 
Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclona...
Website: https://www.humanigen.com/
Founded: 2000
CEO: Cameron Durrant
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Share this website to your friends
The information provided in this report about HGEN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.